Your Health, We Care
Coadministration of Belzutifan with inhibitors of UGT2B17 or CYP2C19 increases plasma exposure of belzutifan, which may increase the incidence and severity of adverse reactions of Belzutifan. Monitor for anemia and hypoxia and reduce the dosage of Belzutifan as recommended.
Coadministration of Belzutifan with CYP3A4 substrates decreases concentrations of CYP3A substrates, which may reduce the efficacy of these substrates. The magnitude of this decrease may be more pronounced in patients who are dual UGT2B17 and CYP2C19 poor metabolizers . Avoid coadministration of Belzutifan with sensitive CYP3A4 substrates, for which minimal decrease in concentration may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its Prescribing Information.
Hormonal Contraceptives Coadministration of Belzutifan with hormonal contraceptives may lead to contraceptive failure or an increase in breakthrough bleeding.
FDA，2021.08
